Shosaikoto (kampo medicine) protects macrophage function from suppression by hypercholesterolemia.
The feeding of cholesterol-enriched diet for 2 weeks was enough to reduce nitric oxide (NO), prostaglandin E(2) (PGE(2) and interleukin-1 (IL-1) productions in thioglycollate-elicited murine macrophages. Although not showing anti-hypercholesterolemic action against ICR mice, Shosaikoto, a Kampo medicine, partially prevented the reduction of NO and IL-1 productions induced by the feeding of cholesterol-enriched diet, and completely released the reduction of PGE(2) production. These data suggest that the malfunction of macrophage induced by hypercholesterolemia may contribute to early atherogenesis and that Shosaikoto retains macrophage function to prevent the development of atherosclerosis, even though serum cholesterol is markedly increased.
Inoue
M
M
Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.
Shen
Y R
YR
Ogihara
Y
Y
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D015232:Dinoprostone / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007375:Interleukin-1 / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008516:Medicine, Chinese Traditional; D051379:Mice; D008815:Mice, Inbred Strains; D017942:Nitric Acid / Q000378:metabolism
D002791:Cholesterol, Dietary; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D007375:Interleukin-1; C461321:shosaikoto-go-keishika-shakuyakuto; D017942:Nitric Acid; D015232:Dinoprostone